Q-omics provides the consensus-scored HHATL profile across patient tissues and cancer cell-line models. HHATL expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HHATL is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, HHATL RNA expression shows 17,941 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where HHATL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HHATL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HHATL survival associations across molecular data types. HHATL RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HHATL RNA expression–survival associations across cancer types. High HHATL expression shows unfavorable associations in LUSC, DLBC, HNSC and LAML, but favorable associations in ACC and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HHATL RNA expression.
This table summarizes HHATL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for HHATL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HHATL shows lower tumor expression in COAD, HNSC, LUSC, BRCA and THCA and higher tumor expression in KICH. The COAD box plot shows higher HHATL RNA expression in normal versus tumor tissue (log2 FC = −0.120, t-test p < 0.001).
This table shows molecular features associated with HHATL in patient tissues and cancer cell lines. In patient samples, HHATL shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HHATL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and SOFT_TISSUE.
